MedWatch

Zealand-CEO: We are creating the biotech-model for the future

Led by Zealand Pharma Danish biotech is now taking things one step further to the next generation of public companies, according to the CEO who dismisses the advice of Big Pharma. A second major biotech company is in agreement.

Foto: Niels Hougaard / Jyllands-Posten

From the turn of the millennium a great many biotech companies went public and the stock prices of most of these plummeted rapidly. Among these companies was Genmab, which went public in 2000 with Pharmexa (now Affitech). In 2005 it was Topotarget’s turn and in 2006 Lifecycle Pharma (now Veloxis Pharmaceuticals headed to the stock market.

Zealand Pharma managed to go public in 2010 following a period of problems and delays, and because of setback after setback the Danish biotech industry has generally shelved the dreams of going public for a while.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier